{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T05:24:26Z","timestamp":1782451466837,"version":"3.54.5"},"reference-count":80,"publisher":"Korean Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-enm.org"],"crossmark-restriction":true},"short-container-title":["Endocrinol Metab"],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:p>The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and\/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer\u2019s disease.<\/jats:p>","DOI":"10.3803\/enm.2022.1642","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T08:01:43Z","timestamp":1675670503000},"page":"25-33","update-policy":"https:\/\/doi.org\/10.3803\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond"],"prefix":"10.3803","volume":"38","author":[{"given":"Adie","family":"Viljoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2119","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1902.sp000920"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1139\/o71-122"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(87)81430-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/jci112855"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.10.3434"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(87)91194-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.47.7.1046"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/endo-123-4-2009"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(94)90164-3"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/bf01316798"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/jci990"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/bf00401145"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/bf00401846"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.44.9.1126"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1996.271.3.e458"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050903"},{"key":"ref17","first-page":"824","volume-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","author":"Zander","year":"2002"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)42531-8"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60659-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2479"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-017-9277-x"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118796810"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)61206-4"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61267-7"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60976-4"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(13)70214-6"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30024-x"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2019.101117"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30092-x"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(17)30085-2"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30311-0"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00174-1"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00213-0"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31271-1"},{"key":"ref39","first-page":"2272","volume-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 Trial","author":"Rodbard","year":"2019"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509225"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141"},{"key":"ref46","first-page":"1519","volume-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","author":"Hernandez","year":"2018"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1901118"},{"key":"ref48","first-page":"121","volume-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","author":"Gerstein","year":"2019"},{"key":"ref49","first-page":"1338","volume-title":"Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme","author":"Aroda","year":"2022"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13353"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001706"},{"key":"ref52","first-page":"2118","volume-title":"A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","author":"Butler","year":"2013"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"ref54","first-page":"5","volume-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","author":"Nauck","year":"2021"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102189"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01062-2"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01041-7"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(21)00203-5"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26164822"},{"key":"ref62","volume-title":""},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(19)30249-9"},{"key":"ref64","first-page":"2042018819865398","volume-title":"The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists","author":"van Baar","year":"2019"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00747-3"},{"key":"ref66","volume-title":""},{"key":"ref67","volume-title":""},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14651"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac018"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab578"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13697"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2775"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00803-x"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028395"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.10.001"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1172\/jci68295"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057848"},{"key":"ref78","volume-title":""},{"key":"ref79","volume-title":""},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925"}],"container-title":["Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-enm.org\/upload\/pdf\/enm-2022-1642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-enm.org\/journal\/view.php?doi=10.3803\/EnM.2022.1642","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-enm.org\/upload\/pdf\/enm-2022-1642.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T05:53:34Z","timestamp":1683006814000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-enm.org\/journal\/view.php?doi=10.3803\/EnM.2022.1642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.3803\/enm.2022.1642","relation":{},"ISSN":["2093-596X","2093-5978"],"issn-type":[{"value":"2093-596X","type":"print"},{"value":"2093-5978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-12-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}